Abstract
Novel coronavirus (SARS-CoV-2) can infect the respiratory tract and cause severe respiratory syndrome. The excessive inflammatory response is involved in the pathogenicity of the SARS-CoV-2. Symptoms of SARS-CoV-2 are generally associated with immunopathogenesis and may result in pulmonary tissue damage. Melatonin is a natural and multifunctional hormone that is involved in both physiological and pathological conditions in the body, such as immune modulation, anti-inflammation, and antioxidant. Melatonin is found in foods, animal and human milk and increases the expression of anti-inflammatory cytokines and, as an adjuvant treatment in SARS-- CoV-2 infection, it may have considerable therapeutic potential, because of its safety and immunomodulatory effects.
Keywords: Melatonin, SARS-CoV-2, treatment, anti-inflammatory, immunomodulator, natural.
Graphical Abstract
The Natural Products Journal
Title:Melatonin Could Be Beneficial in SARS-CoV-2 Therapy
Volume: 11 Issue: 5
Author(s): Sanaz Baghban Rahimi and Ahmad Hosseinzadeh Adli*
Affiliation:
- Department of Microbiology, Tabriz University of Medical Sciences, Tabriz,Iran
Keywords: Melatonin, SARS-CoV-2, treatment, anti-inflammatory, immunomodulator, natural.
Abstract: Novel coronavirus (SARS-CoV-2) can infect the respiratory tract and cause severe respiratory syndrome. The excessive inflammatory response is involved in the pathogenicity of the SARS-CoV-2. Symptoms of SARS-CoV-2 are generally associated with immunopathogenesis and may result in pulmonary tissue damage. Melatonin is a natural and multifunctional hormone that is involved in both physiological and pathological conditions in the body, such as immune modulation, anti-inflammation, and antioxidant. Melatonin is found in foods, animal and human milk and increases the expression of anti-inflammatory cytokines and, as an adjuvant treatment in SARS-- CoV-2 infection, it may have considerable therapeutic potential, because of its safety and immunomodulatory effects.
Export Options
About this article
Cite this article as:
Rahimi Baghban Sanaz and Adli Hosseinzadeh Ahmad*, Melatonin Could Be Beneficial in SARS-CoV-2 Therapy, The Natural Products Journal 2021; 11 (5) . https://dx.doi.org/10.2174/2210315510999200905130902
DOI https://dx.doi.org/10.2174/2210315510999200905130902 |
Print ISSN 2210-3155 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-3163 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Differential Modulation of Autophagy Contributes to the Protective Effects of Resveratrol and Co-Enzyme Q10 in Photoaged Mice
Current Molecular Pharmacology CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Antagonists of the Vasopressin V1 Receptor and of the β<sub>1</sub>-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes-but the Mechanisms Differ
Current Neuropharmacology The Role of Dietary Compounds in the Therapy of Nicotine-Induced Osteoporosis
Current Drug Targets MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Protective Effects of Anesthetics on the Spinal Cord
Current Pharmaceutical Design Molecular Mechanisms of Liver Cancer
Anti-Cancer Agents in Medicinal Chemistry Contribution of Stem Cells to Kidney Repair
Current Stem Cell Research & Therapy Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI
Current Pharmaceutical Design Pharmacological Inhibition of Poly(ADP-ribose) Polymerase in Cardiovascular Disorders: Future Directions
Current Vascular Pharmacology Danshen (Salvia miltiorrhiza Bunge): A Prospective Healing Sage for Cardiovascular Diseases
Current Pharmaceutical Design Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ
Current Topics in Medicinal Chemistry Advanced Glycation End Products in Chinese Medicine Mediated Aging Diseases: A Review
Current Vascular Pharmacology Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: No Reflow: What’s in a Name?)
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Luteolin Inhibits Smooth Muscle Cell Migration and Proliferation by Attenuating the Production of Nox4, P-Akt and VEGF in Endothelial Cells
Current Pharmaceutical Biotechnology